4Vote!
Market Wire (Free subscription) | 12/02/2009
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at the Deutsche Bank 2009 Biotech Boston Confab on Tuesday, December 15, 2009, at 8:00 a.m. EST. The conference will be held at the Four Seasons Hotel in Boston, Massachusetts.
+Vote!
Market Watch (Free subscription) | 11/30/2009
BOSTON (MarketWatch) -- Drug stocks were split in early action Monday as shares of Theravance Inc. slid on news that U.S. regulators have refused to approve its pneumonia treatment telavancin until they receive more supporting information on the product. The NYSE Arca Pharmaceutical Index declined 0.4% to 306.03 as the NYSE Arca Biotechnology Index advanced 0.4% to 889.44. Shares of...
7Vote!
Market Wire (Free subscription) | 11/27/2009
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to the telavancin New Drug Application (NDA) for the treatment of nosocomial pneumonia (NP). Telavancin is a bactericidal, once-daily injectable investigational antibiotic for the treatment of NP caused...
+Vote!
SeekingAlpha.com (Free subscription) | 11/26/2009
The FDA is anticipated to decide on 11/26/09 for Vibativ (telavancin) as a once-daily injectable antibiotic for the treatment of hospital-acquired pneumonia (HAP). But both the market and myself are expecting a delay in approval from the FDA. On November 5, 2009, Theravance, Inc. ( THRX ) announced that the company, in collaboration with Astellas Pharma Inc. ( ALPMF.PK ) will...
3Vote!
Medical News Today (Free subscription) | 11/06/2009
Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including...
5Vote!
Market Wire (Free subscription) | 11/05/2009
SOUTH SAN FRANCISCO, CA and DEERFIELD, IL (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV(TM) (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI)...
5Vote!
Market Wire (Free subscription) | 11/03/2009
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the 18th Annual Credit Suisse Health Care Conference on Thursday, November 12, 2009, at 10:30 a.m. MST. The conference will be held from November 11-13, 2009 at the Arizona Biltmore in Phoenix, Arizona.
6Vote!
Market Wire (Free subscription) | 10/28/2009
TOKYO and SOUTH SAN FRANCISCO, CA (MARKET WIRE) Astellas Pharma Inc. (Astellas) and Theravance, Inc. (NASDAQ: THRX) announced today that Astellas Pharma Europe B.V. submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for telavancin, a bactericidal, once-daily injectable lipoglycopeptide antibiotic, for the treatment of nosocomial pneumonia...
5Vote!
Market Wire (Free subscription) | 10/27/2009
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the quarter ended September 30, 2009. Net loss for the third quarter of 2009 was $22.2 million compared with $20.9 million for the same period in 2008. Net loss per share was $0.35 for the third quarter of 2009 compared with a net loss per share of $0.34 for the same period in...
+Vote!
Market Wire (Free subscription) | 10/27/2009
LONDON and SOUTH SAN FRANCISCO, CA (MARKET WIRE) GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the first patient has commenced treatment as part of the Phase III programme being undertaken to develop a next-generation combination treatment for patients with chronic obstructive pulmonary disorder (COPD), a leading cause of chronic illness and death.
4Vote!
Market Wire (Free subscription) | 10/22/2009
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) announced today that it has earned a milestone payment of $20 million for the U.S. Food and Drug Administration (FDA) approval of VIBATIV(TM) (telavancin) and supplying its collaboration partner, Astellas Pharma US, Inc. (Astellas), with the launch inventory for the first commercial sale in the United States....
5Vote!
The San Francisco Business Times (Free subscription) | 10/22/2009
Medicine company Theravance Inc. earned a $20 million milestone payment because its drug telavancin was approved by the Food and Drug Administration in September. (THRX)
5Vote!
Business Week (Free subscription) | 11/27/2009
Picks of the Week: Microsoft, H-P, Goldman, TiVoWall Street analysts give their buy, sell, or hold views on various stocks in the news this week Story Tools Notable Wall Street analyst opinions on stocks in the news for the week of Nov. 23-27: Nov. 27 QLT Inc. () RBC Capital upgrades to outperform from sector perform; raises price target RBC Capital analyst Douglas Miehm said on Nov. 27 that...
3Vote!
GuruFocus Updates (Free subscription) | 11/15/2009
... is 1.41%. News Corp. had an annual average earning growth of 17.2% over the past 5 years. No. 2: Theravance Inc. (), Weightings: 11.67% - 9,033,741 SharesTheravance Inc is focused on the discovery, development and commercialization of small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, overactive...
